Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer

Journal of International Medical Research

Volumn 42, Issue 5, 2014, Pages 1085-1092

  Wang, Li ^a   Lin, Ying Li ^b   Li, Bo ^a   Wang, Yu Zhong ^a   Li, Wen Ping ^c   Ma, Jian Guo ^c  

^a HEBEI UNIVERSITY OF ENGINEERING   (China)

^b Xuzhou Tumour Hospital   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

cadherin 13; methylation; Prostate cancer; serum

Indexed keywords

CADHERIN; CADHERIN 13; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; H-CADHERIN;

AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DNA METHYLATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PROMOTER REGION; PROSPECTIVE STUDY; PROSTATE CANCER; BLOOD; CANCER GRADING; CASE CONTROL STUDY; COMPARATIVE STUDY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; SURVIVAL RATE;

AGED; CADHERINS; CASE-CONTROL STUDIES; DNA METHYLATION; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 84907204992     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060514540631     Document Type: Article

References (25)

1. Siegel R,Naishadham D,Jemal A.Cancer statistics, 2013.CA Cancer J Clin. 2013;63:11-30
2. Wallace TJ,Torre T,Grob M, et al.Current approaches, challenges and future directions for monitoring treatment response in prostate cancer.J Cancer. 2014;5:3-24
3. Majumdar S,Buckles E,Estrada J, et al.Aberrant DNA methylation and prostate cancer.Curr Genomics. 2011;12:486-505
4. Chao C,Chi M,Preciado M, et al.Methylation markers for prostate cancer prognosis: a systematic review.Cancer Causes Control. 2013;24:1615-1641
5. Tilandyová P,Kajo K,Kliment J, et al.Detection of DNA hypermethylation as a potential biomarker for prostate cancer.Klin Onkol. 2010;23:293-299
6. Moritz R,Ellinger J,Nuhn P, et al.DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer.Anticancer Res. 2013;33:5249-5254
7. Henrique R,Oliveira AI,Costa VL, et al.Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer.BMC Genomics. 2013;14:898-898
8. Swarup V,Rajeswari MR.Circulating (cell-free) nucleic acids – a promising, non-invasive tool for early detection of several human diseases.FEBS Lett. 2007;581:795-799
9. Sturgeon SR,Balasubramanian R,Schairer C, et al.Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls.Epigenetics. 2012;7:1258-1267
10. Ahmed H.Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples.Biomark Cancer. 2010;2:17-33
11. Andreeva AV,Kutuzov MA.Cadherin 13 in cancer.Genes Chromosomes Cancer. 2010;49:775-790
12. Lin YL,He ZK,Li ZG, et al.Downregulation of CDH13 expression promotes invasiveness of bladder transitional cell carcinoma.Urol Int. 2013;90:225-232
13. Lin YL,Sun G,Liu XQ, et al.Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.J Int Med Res. 2011;39:179-186
14. Phé V,Cussenot O,Rouprêt M.Methylated genes as potential biomarkers in prostate cancer.BJU Int. 2010;105:1364-1370
15. Maruyama R,Toyooka S,Toyooka KO, et al.Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features.Clin Cancer Res. 2002;8:514-519
16. Gleason DF,Mellinger GT.Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.1974. J Urol. 2002;167:953-958
17. American Joint Committee on Cancer. Cancer staging references, https://cancerstaging.org/references-tools/Pages/What-is-Cancer-Staging.aspx (2014, accessed 1 July 2014).
18. Prostate cancer. NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2004;2:224-248
19. Sunami E,Shinozaki M,Higano CS, et al.Multimarker circulating DNA assay for assessing blood of prostate cancer patients.Clin Chem. 2009;55:559-567
20. Lin YL,Liu XQ,Li WP, et al.Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.Int Urol Nephrol. 2012;44:111-117
21. Henrique R,Ribeiro FR,Fonseca D, et al.High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.Clin Cancer Res. 2007;13:6122-6129
22. Suvà ML,Riggi N,Bernstein BE.Epigenetic reprogramming in cancer.Science. 2013;339:1567-1570
23. Kulis M,Esteller M.DNA methylation and cancer.Adv Genet. 2010;70:27-56
24. Goering W,Kloth M,Schulz WA.DNA methylation changes in prostate cancer.Methods Mol Biol. 2012;863:47-66
25. Alumkal JJ,Zhang Z,Humphreys EB, et al.Effect of DNA methylation on identification of aggressive prostate cancer.Urology. 2008;72:1234-1239